7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Anavex Life Sciences Corp
(NASDAQ:AVXL) 

AVXL stock logo

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Pha...

Founded: 2004
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Anavex Life Sciences Corp Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.36-0.31-0.26-0.21-0.15-0.1-0.050
Anavex Life Sciences Corp Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.36-0.31-0.26-0.21-0.15-0.1-0.050
Anavex Life Sciences Corp Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.280.570.851.131.411.71.98
Anavex Life Sciences Corp (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -20.01-17.15-14.29-11.43-8.57-5.72-2.860
Anavex Life Sciences Corp P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.931.862.793.724.655.576.5
No extra charts and metrics for this ticker.